Encouraging fair pricing, fair access, and future innovation within the US health care system | RTs not endorsements
Boston, MA
Joined January 2012
- Tweets2.9K
- Following627
- Followers5.4K
- Likes312
Institute for Clinical and Economic Review to Assess Therapy for Treatment-Resistant Depression: icer.org/wp-content/uploads/…
ICER and @WestHealth released a new “Launch Price and Access Report,” finding that the median drug launch prices continue to exceed $250,000 per year, contributing to increases in overall healthcare costs. Read more: shorturl.at/qAL1J
#DrugPricing #PatientAccess #RxPricing
ICER retweeted
"You're going to get government intervention, and it's going to be crappy." -- @icer_review's Sarah Emond at the @statnews Summit on what will happen if the healthcare system doesn't adopt a voluntary, value-focused approach to prices.
Many thanks to @statnews for inviting ICER's President and CEO Sarah Emond to speak as a panelist alongside @NPLB_org Priscilla VanderVeer at this year's #STATSummit!
When moderator ed silverman asked for one short-term solution to address the drug pricing problem in the US, Sarah highlighted the importance of tying drug price to value.
ICER #WeeklyView: an ICER Webinar, Draft Report, & Covid vax for pregnant women conta.cc/4s69s6s
Today, ICER released a Draft Evidence Report assessing the comparative clinical effectiveness and value of two new treatments for Friedreich’s Ataxia, a #rare, #genetic disorder: tinyurl.com/ycy8fb67
This draft is now open to public comments until November 11th.
On Oct 20, ICER and @WestHealth are releasing our 2026 Launch Price and Access Report.
On Oct 27th, join us for a #webinar to discuss the report findings. Register here: shorturl.at/MdkFd
#patientaccess #affordability #evidencebased #prescriptiondrugs #valuebased
ICER #WeeklyView: HEMA Draft Report, an ICER webinar, & impact of Rx prices on employers conta.cc/4rSUj8F
On Oct 20, ICER and @WestHealth are releasing our 2026 Launch Price and Access Report.
On Oct 27th, join us for a #webinar to discuss the report findings. Register here: shorturl.at/MdkFd
#patientaccess #affordability #evidencebased #prescriptiondrugs #valuebased
The Health Economics Methods Advisory (#HEMA) today released a Draft Report on how HTA bodies can evaluate, present, and communicate uncertainty in #healtheconomic evaluations. #hta #populationhealth
Now accepting public comments until Nov 2. Read more: shorturl.at/mOe0F
ICER #WeeklyView: A Parkinson’s approval and upcoming hypertension public meeting conta.cc/3Vro8B0
Institute for Clinical and Economic Review Releases Evidence Report on Treatments for Hypertension: icer.org/news-insights/press…
ICER #WeeklyView: Sarah Emond on the Business Group on Health podcast & Parkinson’s public meeting conta.cc/4yww6aV
The @BizGrpHlth podcast recently interviewed ICER’s President and CEO, Sarah K. Emond, MPP about the affordability of cell and gene therapies.
Listen now: businessgrouphealth.org/reso…
On October 1st, ICER will host a virtual public meeting to discuss tavapadon, a treatment for #Parkinson’s disease.
Register here: events.zoom.us/ev/AmUenZ7-CL…
Today's Weekly View includes ICER President and CEO Sarah Emond's perspective on the apitegromab approval (now branded Isembyld). Read here: conta.cc/4y2W6dF
#isembyld #DrugPricing #PharmaPricing #ValueBasedPricing #MarketAccess #Healthcare
ICER #WeeklyView: Parkinson’s disease report & more on MFN, biosimilars, prior auth conta.cc/4y2W6dF
Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Parkinson’s Disease: icer.org/pressreleases/insti…